cyclacel
presents
phase
clinical
data
showing
safety
activity
good
oral
bioavailability
fadraciclib
patients
advanced
solid
tumors
symposium
berkeley
heights
globe
newswire
cyclacel
pharmaceuticals
nasdaq
cycc
nasdaq
cyccp
cyclacel
company
biopharmaceutical
company
developing
innovative
medicines
based
cancer
cell
biology
announced
clinical
data
demonstrating
safety
activity
good
oral
bioavailability
cyclacel
inhibitor
fadraciclib
patients
advanced
solid
tumors
data
presented
oral
presentation
plenary
session
ena
symposium
held
virtually
october
addition
good
oral
bioavailability
pleased
report
durable
pr
continuing
shrinkage
target
lesions
reaching
patient
amplified
endometrial
cancer
four
patients
achieved
stable
disease
said
spiro
rombotis
chief
executive
officer
cyclacel
data
support
clinical
development
fadraciclib
planned
phase
study
advanced
endometrial
ovarian
cancer
inhibitor
resistant
breast
cancer
along
safety
efficacy
study
evaluate
cyclin
e
myc
biomarkers
relevant
fadraciclib
mechanism
action
addition
studies
solid
tumors
encouraged
evidence
antileukemic
activity
studies
fadraciclib
hematological
malignancies
looking
forward
reporting
updated
data
ongoing
studies
fadraciclib
selective
presentation
highlights
phase
safety
pharmacokinetic
pharmacodynamic
study
fadraciclib
kinase
inhibitor
patients
advanced
cancers
heavily
pretreated
patients
various
advanced
solid
tumors
including
ovarian
endometrial
uterine
breast
fallopian
cancer
enrolled
part
intravenous
administration
five
patients
part
oral
administration
ongoing
phase
open
label
dose
escalation
study
primary
objective
determine
mtd
recommended
phase
dose
secondary
objectives
evaluate
pharmacokinetics
assess
pharmacodynamic
markers
design
administration
schedule
flat
dosing
schedule
fadraciclib
given
either
infusion
orally
days
every
weeks
safety
trial
advanced
four
dose
levels
dl
range
administered
intravenous
infusion
days
two
dl
range
orally
administered
formulation
days
cycles
eleven
patients
treated
mg
dose
limiting
toxicity
reversible
neutropenia
dose
level
expanded
define
major
unexpected
toxicities
observed
efficacy
formulation
one
confirmed
partial
response
two
stable
disease
sd
patients
formulation
pr
month
half
fadraciclib
endometrial
cancer
failed
seven
lines
prior
therapy
continuing
treatment
months
reduction
target
tumor
lesions
sd
cyclin
e
amplified
ovarian
cancer
tumor
shrinkage
four
months
sd
fallopian
tube
adenocarcinoma
undetermined
protein
level
pharmacokinetics
pk
increases
fadraciclib
exposure
increasing
dosing
levels
high
oral
bioavailability
comparable
pk
profile
oral
administration
presentation
part
ena
symposium
available
presentation
events
section
cyclacel
website
https
events
presentation
details
title
phase
safety
pharmacokinetic
pharmacodynamic
study
fadraciclib
cyclin
dependent
kinase
inhibitor
patients
advanced
cancers
session
title
late
breaking
best
proffered
papers
session
date
time
saturday
october
cet
presentation
number
kinases
fadraciclib
kinases
cdks
critical
cell
cycle
regulation
transcriptional
elongation
dysregulated
cdks
linked
cancer
hallmarks
uncontrolled
proliferation
increased
survival
fadraciclib
potent
orally
intravenously
available
inhibitor
fadraciclib
ongoing
phase
study
patients
advanced
solid
tumors
part
study
target
engagement
durable
suppression
biomarker
observed
single
dose
fadraciclib
infusion
tumor
shrinkage
stable
disease
observed
five
patients
cyclin
e
myc
amplified
advanced
cancers
treated
ongoing
part
study
evaluating
intensive
dosing
regimen
heavily
pretreated
patient
amplified
endometrial
cancer
achieved
radiographically
confirmed
partial
response
pr
month
half
fadraciclib
patient
continues
therapy
year
reduction
target
tumor
lesions
reached
additional
patient
cyclin
e
amplified
ovarian
cancer
achieved
stable
disease
tumor
shrinkage
part
investigating
oral
dose
formulation
fadraciclib
also
evaluated
phase
combination
studies
venetoclax
relapsed
refractory
cll
relapsed
refractory
aml
mds
similarly
inhibitors
fadraciclib
may
useful
combination
anticancer
drugs
including
inhibitors
venetoclax
inhibitors
trastuzumab
preclinical
data
suggest
fadraciclib
may
benefit
patients
adult
pediatric
hematological
malignancies
cll
aml
lymphomas
multiple
myeloma
certain
cyclin
solid
tumors
including
certain
forms
breast
cancer
neuroblastoma
ovarian
cancer
uterine
serous
carcinoma
cyclacel
pharmaceuticals
cyclacel
pharmaceuticals
biopharmaceutical
company
developing
innovative
cancer
medicines
based
cell
cycle
transcriptional
regulation
dna
damage
response
biology
transcriptional
regulation
program
evaluating
fadraciclib
single
agent
solid
tumors
combination
venetoclax
patients
relapsed
refractory
aml
mds
cll
program
evaluating
inhibitor
advanced
leukemias
mds
patients
dna
damage
response
program
evaluating
oral
combination
sapacitabine
venetoclax
patients
relapsed
refractory
aml
mds
trial
ist
evaluating
oral
combination
sapacitabine
olaparib
patients
brca
mutant
breast
cancer
cyclacel
strategy
build
diversified
biopharmaceutical
business
focused
hematology
oncology
based
pipeline
novel
drug
candidates
additional
information
please
visit
statements
news
release
contains
certain
statements
involve
risks
uncertainties
could
cause
actual
results
materially
different
historical
results
future
results
expressed
implied
statements
statements
include
statements
regarding
among
things
efficacy
safety
intended
utilization
cyclacel
product
candidates
conduct
results
future
clinical
trials
plans
regarding
regulatory
filings
future
research
clinical
trials
plans
regarding
partnering
activities
factors
may
cause
actual
results
differ
materially
include
risk
product
candidates
appeared
promising
early
research
clinical
trials
demonstrate
safety
efficacy
later
clinical
trials
trials
may
difficulty
enrolling
cyclacel
may
obtain
approval
market
product
candidates
risks
associated
reliance
outside
financing
meet
capital
requirements
risks
associated
reliance
collaborative
partners
clinical
trials
development
commercialization
product
candidates
urged
consider
statements
include
words
may
would
could
believes
estimates
projects
potential
expects
plans
anticipates
intends
continues
forecast
designed
goal
negative
words
comparable
words
uncertain
list
description
risks
uncertainties
company
faces
please
refer
recent
annual
report
form
periodic
filings
cyclacel
files
securities
exchange
commission
available
statements
current
date
made
cyclacel
assumes
obligation
update
statements
whether
result
new
information
future
events
otherwise
contacts
company
paul
mcbarron
pmcbarron
investor
relations
russo
partners
llc
eric
ando
copyright
cyclacel
pharmaceuticals
rights
reserved
cyclacel
logo
trademarks
cyclacel
pharmaceuticals
inc
